Inventiva (NASDAQ:IVA) Coverage Initiated at HC Wainwright

Key Points

• Inventiva (NASDAQ:IVA) received a "buy" rating from HC Wainwright, with a price target of $20.00, indicating a potential upside of 280.23% from its current price.
• Current analyst ratings show a consensus of five "buy" ratings and one "hold" rating, with an average target price of $14.83 according to MarketBeat.com.
• Inventiva specializes in developing oral small molecule therapies for conditions like non-alcoholic steatohepatitis (NASH), with its lead product candidate, Lanifibranor, currently in Phase III clinical trials.

Analysts at HC Wainwright started coverage on shares of Inventiva (NASDAQ:IVA - Get Free Report) in a research report issued on Wednesday, MarketBeat reports. The firm set a "buy" rating and a $20.00 price target on the stock. HC Wainwright's price objective indicates a potential upside of 252.73% from the stock's current price.

A number of other research analysts have also issued reports on IVA. Piper Sandler began coverage on Inventiva in a report on Wednesday, August 27th. They issued an "overweight" rating and a $26.00 target price for the company. Guggenheim upped their price target on Inventiva from $9.00 to $13.00 and gave the company a "buy" rating in a report on Tuesday. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, Inventiva has a consensus rating of "Moderate Buy" and a consensus target price of $14.83.

Inventiva Stock Up 7.8%

Shares of IVA traded up $0.41 during mid-day trading on Wednesday, hitting $5.67. 31,832 shares of the company's stock were exchanged, compared to its average volume of 22,008. The stock's 50-day moving average is $3.75 and its 200-day moving average is $3.41. Inventiva has a fifty-two week low of $1.53 and a fifty-two week high of $6.50.

Hedge Funds Weigh In On Inventiva

An institutional investor recently bought a new position in Inventiva stock. Wealth Enhancement Advisory Services LLC acquired a new position in Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,715 shares of the company's stock, valued at approximately $32,000. 19.06% of the stock is currently owned by institutional investors.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.